Editing Bisphosphonate (section)

===Post-menopausal osteoporosis===
Bisphosphonates are recommended as a first line treatments for post-menopausal osteoporosis.<ref name=AACE2010>{{cite journal | pmid = 21224201 | pmc=4876714 | volume=16 | title=American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis | year=2010 | journal=Endocr Pract | pages=1–37 |vauthors=Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM | issue=Suppl 3 | doi=10.4158/ep.16.s3.1}}</ref><ref>{{cite journal |title=Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society |journal=Menopause |volume=17 |issue=1 |pages=25–54; quiz 55–6 |year=2010 |pmid=20061894 |doi=10.1097/gme.0b013e3181c617e6 |s2cid=7980731}}</ref><ref>{{cite journal |author=Hauk L |title=ACOG releases practice bulletin on osteoporosis |journal=Am Fam Physician |volume=88 |issue=4 |pages=269–75 | date=August 2013|pmid=23944732 }}</ref><ref>{{cite journal |vauthors=Compston J, Bowring C, Cooper A |title=Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013 |journal=Maturitas |volume=75 |issue=4 |pages=392–6 | date=August 2013|pmid=23810490 |doi=10.1016/j.maturitas.2013.05.013 |display-authors=etal|doi-access=free }}</ref>

Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment.<ref name="Eriksen EF, Díez-Pérez A, Boonen S 126–35"/> The bisphosphonate alendronate  reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral fractures by 62%.<ref name="Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G 1005–14"/><ref name="gauthier"/> Risedronate has also been shown to reduce the risk of hip fractures.<ref name=AACE2010/><ref name="Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY 23–57"/>

After five years of medications by mouth or three years of intravenous medication among those at low risk, bisphosphonate treatment can be stopped.<ref name=Ad2016/> In those at higher risk ten years of medication by mouth or six years of intravenous treatment may be used.<ref name=Ad2016>{{cite journal|last1=Adler|first1=Robert A|last2=El-Hajj Fuleihan|first2=Ghada|last3=Bauer|first3=Douglas C|last4=Camacho|first4=Pauline M|last5=Clarke|first5=Bart L|last6=Clines|first6=Gregory A|last7=Compston|first7=Juliet E|last8=Drake|first8=Matthew T|last9=Edwards|first9=Beatrice J|last10=Favus|first10=Murray J|last11=Greenspan|first11=Susan L|last12=McKinney|first12=Ross|last13=Pignolo|first13=Robert J|last14=Sellmeyer|first14=Deborah E|title=Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research|journal=Journal of Bone and Mineral Research|date=January 2016|volume=31|issue=1|pages=16–35|doi=10.1002/jbmr.2708|pmid=26350171|pmc=4906542}}</ref>